Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics
Key facts
- Who runs it
- Chungnam National University Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 28 Feb 2028
- Type of study
- Observational, 2 groups
- Record updated
- 18 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment
- Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of:
- Uncontrolled diabetes.Coagulation disorders
- Thrombocytopenia (platelet count $< 100,000)
- A history of cirrhosis diagnosis
- Current receipt of low molecular weight heparin
- Current use of platelet inhibitors
- A history of posterior spinal fusion that may interfere with catheter insertion
- Local skin infection or rash at the puncture site
- Signs of systemic infection or sepsis
- A history of lumbar puncture within the past 6 hours
Who cannot take part
- Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest
- Patients with a history of acute or chronic brain disease
- Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery
- Patients who underwent extracorporeal membrane oxygenation (ECMO)
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.
Read full original descriptionShow less
The main question this study aims to answer is:
Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?
To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.
The 2 groups in the trial
- Favorable neurological outcome
The favorable neurological outcome group is classified as patients with a CPC score of 1 or 2 upon long-term follow-up (at discharge, 3 months after post-resuscitation)
- Unfavorable neurological outcome
The favorable neurological outcome group is classified as patients with a CPC score of 3 to 5 upon long-term follow-up (at discharge, 3 months after post-resuscitation)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Identification of Novel Molecular Pathophysiological Mechanisms of Secondary Brain Injury in Post-cardiac Arrest Syndrome Patients Using Cerebrospinal Fluid Multi-omics Analysis
- Record updated
- 18 March 2026